Interim

Directorate change

Retrieved on: 
Wednesday, April 10, 2024
Justine, AstraZeneca, Aquaculture, Operations director, Interim, Arthur Andersen, Finance, United Utilities

Justine joined OTAQ in July 2023 as Interim Chief Financial Officer.

Key Points: 
  • Justine joined OTAQ in July 2023 as Interim Chief Financial Officer.
  • Prior to this, she held a number of senior positions in a range of high growth companies across various sectors including property development, aviation charter services, IT and construction.
  • Most recently Justine was Managing Director of GB3 Limited, an IT Managed Services company, having joined the company in 2012 as Finance and Operations Director.
  • Before GB3 Limited, Justine worked for United Utilities and AstraZeneca having previously qualified as a Chartered Accountant with Arthur Andersen.

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

Retrieved on: 
Tuesday, April 9, 2024
Data monitoring committee, Cirrhosis, Metabolism, Disease, Risk, Patient, Hope, MASH, Final Analysis, Therapy, GALT, Safety, DSMB, Interim, Plasma protein binding, Esophageal varices, Liver, Pharmaceutical industry

The objective of this fifth DSMB meeting was to further review the emerging tolerance and safety profiles of belapectin.

Key Points: 
  • The objective of this fifth DSMB meeting was to further review the emerging tolerance and safety profiles of belapectin.
  • Based on its deliberation, which included an unblinded review of the data collected thus far, the DSMB concluded that NAVIGATE can continue as designed, without modifications.
  • The Phase 2b/3 NAVIGATE study is a global, seamless, adaptive, randomized, placebo-controlled, double-blind trial.
  • Enrolled patients have been randomized to receive every two weeks a blinded infusion of belapectin at 2 mg/kg/LBM or 4 mg/kg/LBM or placebo.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

Retrieved on: 
Monday, April 8, 2024
Zebra, News, LLP, Bank statement, Therapy, Pomerantz, Interim, Audit committee, Audit

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA).
  • The investigation concerns whether Zevra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Monday, April 8, 2024
Prior, CFO, SVP, Zymeworks, News, LLP, Senior, Interim management, Pomerantz, Interim

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Astec Industries, Inc. (NASDAQ: ASTE) Announces the Company’s First Quarter Conference Call on May 1, 2024 at 8:30 A.M. Eastern Time

Retrieved on: 
Monday, April 8, 2024
Engineering Council of India, ASTE, Interim, Senior, Conference, Administration, Lobster

CHATTANOOGA, Tenn., April 08, 2024 (GLOBE NEWSWIRE) -- You are invited by Astec Industries, Inc. (NASDAQ:ASTE) to participate in a conference call to review the company’s first quarter 2024 financial results.

Key Points: 
  • CHATTANOOGA, Tenn., April 08, 2024 (GLOBE NEWSWIRE) -- You are invited by Astec Industries, Inc. (NASDAQ:ASTE) to participate in a conference call to review the company’s first quarter 2024 financial results.
  • Astec Industries, Inc. will be releasing the company’s first quarter results to the wire service on Wednesday, May 1, 2024 at approximately 7:00 a.m. Eastern Time.
  • The live call will begin on Wednesday, May 1, 2024 at 8:30 a.m. Eastern Time.
  • A replay of the call can be accessed through May 15, 2024 by dialing (800) 770-2030, or (609) 800-9909 for international callers, Conference ID# 8741406.

ASDS/A Board of Directors Appoints Tara Azzano as Executive Director

Retrieved on: 
Monday, April 8, 2024
Research, Diagnosis, Executive, Patient, Association management, FRCPC, Society, Interim, Meeting, ASDS, Medicine, Management

Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.

Key Points: 
  • Schaumburg, IL, April 08, 2024 (GLOBE NEWSWIRE) -- Tara L. Azzano was recently named Executive Director of the American Society for Dermatologic Surgery (ASDS), the largest specialty organization in the U.S. exclusively representing dermatologic surgeons.
  • She joined the organization in 2002 as the Director of Education, Research and Meetings.
  • Azzano has almost a quarter of a century’s worth of experience with ASDS/A, and her institutional knowledge of our Society is unprecedented.
  • “I am truly thrilled to have been chosen as the next Executive Director and to continue to share my passion for dermatologic surgery.

NatureServe Expands Access to Critical Biodiversity Data with the Launch of NatureServe Explorer Pro

Retrieved on: 
Friday, April 5, 2024
CIO, Science, Exploration, Research, Classification, Biodiversity, NatureServe, Interim, Animal

The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.

Key Points: 
  • The advanced platform provides users with unparalleled access to detailed information on at-risk species, reinforcing NatureServe's commitment to conserving biodiversity as the go-to source for decision-quality biodiversity data.
  • NatureServe Explorer Pro offers users high-quality biodiversity information for data-driven conservation planning and environmental screening.
  • “NatureServe Explorer Pro is a critical open data platform for discovery, exploration, and dissemination of biodiversity data,” said Patrick Henry, Executive Director of NatureServe Canada.
  • “With powerful mapping tools and detailed data, NatureServe Explorer Pro expands our capacity to deliver high-quality scientific information,” said Lori Scott, Interim CEO and CIO of NatureServe.

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries

Retrieved on: 
Friday, April 5, 2024
HMO, Pressure, Patient, Food and Drug Administration, Health care, Safety, Interim, Clalit Health Services, FDA, Health, Food

PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.

Key Points: 
  • PressureSafe™ uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care.
  • In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries.
  • Patient care cost per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries.
  • Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Brooge Energy Limited - BROG

Retrieved on: 
Friday, April 5, 2024
Order, Prior, BROG, Ext, Acquisition, Sale, LLP, News, Complaint, Fraud, Pomerantz, Interim, Action Replay, Court, Cryptocurrency

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Brooge Energy Limited (“Brooge” or the “Company”) (NASDAQ: BROG).

Key Points: 
  • NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Brooge Energy Limited (“Brooge” or the “Company”) (NASDAQ: BROG).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Brooge and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

OLAPLEX Announces CFO Transition

Retrieved on: 
Thursday, April 4, 2024
CFO, Partnership, Alvarez and Marsal, Restaurant, Interim management, Interim, Telecommunications, Alvarez

The company has launched an external search for a new CFO in partnership with a leading executive search firm.

Key Points: 
  • The company has launched an external search for a new CFO in partnership with a leading executive search firm.
  • While the search is underway, Paul Kosturos, a seasoned financial executive with over 30 years of experience, will join OLAPLEX and serve as Interim CFO following Mr. Tiziani’s departure.
  • Mr. Tiziani will work closely with Mr. Kosturos in the weeks ahead to facilitate a smooth transition.
  • “On behalf of everyone at OLAPLEX, I want to thank Eric for his many contributions to the company,” said Amanda Baldwin, Chief Executive Officer of OLAPLEX.